Fall 2025 - Innovation

Argenx Is Conducting a Phase IV Study to Assess Efgartigimod Ph20 SC to Treat Adult CIDP Patients

Argenx is conducting a Phase IV clinical study titled “A Study to Assess Adults with CIDP Transitioning From IVIG to Efgartigimod PH20 SC” to evaluate how adults with chronic inflammatory demyelinating polyneuropathy (CIDP) transition from intravenous immune globulin (IVIG) treatment to efgartigimod PH20 SC. Efgartigimod PH20 SC, a biological treatment administered via subcutaneous injection, is designed to replace the current IVIG treatment, potentially offering a more accessible and less-invasive option for patients.

In the interventional study that follows a single-group model without masking, participants will transition from IVIG to efgartigimod PH20 SC to assess their adjustment over approximately 17 to 19 weeks. Originally begun on Dec. 10, 2024, with its primary completion and estimated full completion dates yet to be announced, this latest study update was submitted on Aug. 14, 2025, indicating ongoing recruitment and progress.

If successful, efgartigimod PH20 SC would provide an alternative to existing CIDP treatments.

References

  1. Tipranks. Argenx’s Promising CIDP Treatment: A Closer Look at the Efgartigimod PH20 SC Study, Aug. 16, 2025. Accessed at www.theglobeandmail.com/investing/markets/stocks/ARGX/pressreleases/34204435/argenxs-promising-cidp-treatment-a-closer-look-at-the-efgartigimod-ph20-sc-study.
BSTQ Staff
BioSupply Trends Quarterly [BSTQ] is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace. With timely and critical information, each themed issue covers topics ranging from product breakthroughs, industry insights and innovations, up-to-the-minute news on the latest clinical trials, accessibility, and service and safety concerns.